Emre Tokuç
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Emre Tokuç has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Ridvan Kayar
Department of Urology, Haydarpasa Numune Training and Research Hospital, University of Health Sciences, ISTANBUL, Turkey
9 shared publications - Ramazan Topaktas
C Department of Urology , Haydarpasa Training and Research Hospital , Istanbul , Turkey
8 shared publications - Emrah Özsoy
Department of Urology, Ünye Çakırtepe Hospital, Ordu, Türkiye
7 shared publications - Metin Ishak Ozturk
Department of Urology, University of Health Sciences, Haydarpaşa Numune Training and Research Hospital, İstanbul, Turkey
7 shared publications - Musab Ali Kutluhan
Department of Urology, Yildirim Beyazit University School of Medicine, Ankara, Turkey
6 shared publications Metin İsHak Öztürk
Department of Urology, Haydarpasa Numune Training and Research Hospital, University of Health Sciences, ISTANBUL, Turkey
5 shared publications
Latest Publications
- 4 May 2026
- Published by SAGE Publications in Urologia Journal
- Vol. 93 (4) , 796-804
Creatinine and hemoglobin/creatinine ratio as predictors of 12-month recurrence after direct visual internal urethrotomy for short-segment (<2 cm) bulbar urethral strictures
Background: Urethral stricture (US) disease frequently recurs after direct visual internal urethrotomy (DVIU). This study investigated the prognostic value of serum creatinine, estimated glomerular filtration rate (eGFR), and the hemoglobin/creatinine (Hgb/Cre) ratio for predicting 12-month recurrence in short-segment bulbar US. Methods: A retrospective cohort of 237 patients undergoing DVIU for isolated bulbar US p < 0.001), lower eGFR (74.0 vs 88.0 mL/min/1.73 m 2 , p < 0.001), and lower Hgb/Cre ratios (12.13 vs 14.28, p = 0.002). Endoscopic surgery–related etiology was strongly associated with recurrence (70.8% vs 47.0%, p = 0.001), whereas age, hemoglobin, Qmax, and PVR showed no significant relationship. In multivariable models, elevated creatinine (OR 3.47, 95% CI 1.82–6.60), reduced Hgb/Cre ratio (OR 0.90, 95% CI 0.85–0.95), and lower eGFR (OR 0.975, 95% CI 0.964–0.987) independently predicted recurrence. Kaplan–Meier analysis demonstrated significantly higher recurrence in patients with creatinine ⩾ 1.02 mg/dL, eGFR ⩽ 80.5 mL/min/1.73 m 2 , and Hgb/Cre ratio ⩽ 13.26. Conclusions: Elevated serum creatinine, reduced eGFR, and a lower Hgb/Cre ratio are independent predictors of 12-month recurrence following DVIU for short-segment bulbar US. Demographic and uroflowmetric parameters showed limited predictive value, whereas iatrogenic etiology markedly increased recurrence risk. Incorporating renal function markers into risk stratification may guide patient selection and support timely consideration of urethroplasty or drug-coated balloon dilatation (Optilume) in high-risk individuals. Prospective multicenter studies are warranted.
- 4 May 2026
- Published by SAGE Publications in Urologia Journal
- Vol. 93 (4) , 796-804
Creatinine and hemoglobin/creatinine ratio as predictors of 12-month recurrence after direct visual internal urethrotomy for short-segment (<2 cm) bulbar urethral strictures
Background: Urethral stricture (US) disease frequently recurs after direct visual internal urethrotomy (DVIU). This study investigated the prognostic value of serum creatinine, estimated glomerular filtration rate (eGFR), and the hemoglobin/creatinine (Hgb/Cre) ratio for predicting 12-month recurrence in short-segment bulbar US. Methods: A retrospective cohort of 237 patients undergoing DVIU for isolated bulbar US p < 0.001), lower eGFR (74.0 vs 88.0 mL/min/1.73 m 2 , p < 0.001), and lower Hgb/Cre ratios (12.13 vs 14.28, p = 0.002). Endoscopic surgery–related etiology was strongly associated with recurrence (70.8% vs 47.0%, p = 0.001), whereas age, hemoglobin, Qmax, and PVR showed no significant relationship. In multivariable models, elevated creatinine (OR 3.47, 95% CI 1.82–6.60), reduced Hgb/Cre ratio (OR 0.90, 95% CI 0.85–0.95), and lower eGFR (OR 0.975, 95% CI 0.964–0.987) independently predicted recurrence. Kaplan–Meier analysis demonstrated significantly higher recurrence in patients with creatinine ⩾ 1.02 mg/dL, eGFR ⩽ 80.5 mL/min/1.73 m 2 , and Hgb/Cre ratio ⩽ 13.26. Conclusions: Elevated serum creatinine, reduced eGFR, and a lower Hgb/Cre ratio are independent predictors of 12-month recurrence following DVIU for short-segment bulbar US. Demographic and uroflowmetric parameters showed limited predictive value, whereas iatrogenic etiology markedly increased recurrence risk. Incorporating renal function markers into risk stratification may guide patient selection and support timely consideration of urethroplasty or drug-coated balloon dilatation (Optilume) in high-risk individuals. Prospective multicenter studies are warranted.
- 22 December 2025
- Published by Springer Nature in Urolithiasis
- Vol. 54 (1) , 15
Predictive value of renal parenchyma and pelvic urine density on preoperative non-contrast CT in systemic inflammatory response syndrome (SIRS) after semi-rigid ureteroscopy
To evaluate the predictive value of preoperative NCCT (Non-Contrast Computed Tomography) measured renal parenchyma and pelvic urine densities for the development of systemic inflammatory response syndrome (SIRS) following URS. 1262 patients underwent semi-rigid URS due to ureterolithiasis between January 2008 and August 2023 were screened and 286 patients were included. Patient demographics and NCCT findings (stone size, location, density, hydronephrosis, renal parenchymal density, pelvic urine density) were collected retrospectively. Patients were categorized into two groups based on SIRS development after URS. Pelvic urine and parenchyma densities of the obstructed kidney were compared. A multivariate logistic regression analysis was performed to identify independent predictors of SIRS. The median obstructed kidney cortex mean density was significantly lower in the SIRS (+) group compared to the SIRS (-) group (26.67 [22.33–29.50] vs. 33.33 [27.24–37.75]). Obstructed kidney medulla mean density was also significantly lower in patients with SIRS (24.00 [22.33–27.50] vs. 31.50 [26.24–36.75], p = 0.001). Pelvic urine density was significantly higher in the SIRS-positive group. Stone density (OR = 1.35, % 95 CI: 1.09–1.67, p = 0.006), proximal ureteral location (OR = 5.21, % 95 CI: 1.84–14.7, p = 0.002), cortex mean density (OR = 0.91, % 95 CI: 0.87–0.95, p = 0.001) and pelvic urine density (OR = 1.07, % 95 CI: 1.02–1.12, p = 0.010) were stated as significant predictors. Renal parenchyma and pelvic urine density on pre-operative NCCT can predict SIRS after semi-rigid URS.
- 22 December 2025
- Published by Springer Nature in Urolithiasis
- Vol. 54 (1) , 15
Predictive value of renal parenchyma and pelvic urine density on preoperative non-contrast CT in systemic inflammatory response syndrome (SIRS) after semi-rigid ureteroscopy
To evaluate the predictive value of preoperative NCCT (Non-Contrast Computed Tomography) measured renal parenchyma and pelvic urine densities for the development of systemic inflammatory response syndrome (SIRS) following URS. 1262 patients underwent semi-rigid URS due to ureterolithiasis between January 2008 and August 2023 were screened and 286 patients were included. Patient demographics and NCCT findings (stone size, location, density, hydronephrosis, renal parenchymal density, pelvic urine density) were collected retrospectively. Patients were categorized into two groups based on SIRS development after URS. Pelvic urine and parenchyma densities of the obstructed kidney were compared. A multivariate logistic regression analysis was performed to identify independent predictors of SIRS. The median obstructed kidney cortex mean density was significantly lower in the SIRS (+) group compared to the SIRS (-) group (26.67 [22.33–29.50] vs. 33.33 [27.24–37.75]). Obstructed kidney medulla mean density was also significantly lower in patients with SIRS (24.00 [22.33–27.50] vs. 31.50 [26.24–36.75], p = 0.001). Pelvic urine density was significantly higher in the SIRS-positive group. Stone density (OR = 1.35, % 95 CI: 1.09–1.67, p = 0.006), proximal ureteral location (OR = 5.21, % 95 CI: 1.84–14.7, p = 0.002), cortex mean density (OR = 0.91, % 95 CI: 0.87–0.95, p = 0.001) and pelvic urine density (OR = 1.07, % 95 CI: 1.02–1.12, p = 0.010) were stated as significant predictors. Renal parenchyma and pelvic urine density on pre-operative NCCT can predict SIRS after semi-rigid URS.
- Open Access
- 12 December 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (6) , 1459-1465
Predictive impact of PI-RADS 3 lesion volume/total prostate volume ratio in prostate cancer diagnosis in biopsy-naïve patients
Background/aim: To assess the potential of the ratio between PI-RADS 3 lesion volume and total prostate volume as a predictive parameter for guiding the decision to perform a biopsy in patients presenting with PI-RADS 3 lesions on multiparametric prostate magnetic resonance imaging (mpMRI). Materials and methods: A total of 749 patients who underwent mpMRI due to suspected prostate cancer between January 2014 and August 2023 were scanned. Based on predefined inclusion and exclusion criteria, 308 patients were included. Age, total prostate-specific antigen (PSA) value, prostate volume measured in mpMRI, mpMRI result, PI-RADS 3 lesion volume, and biopsy results were collected. The PI-RADS 3 ratio was calculated as PI-RADS 3 lesion volume/total prostate volume. PSA density (dPSA) was calculated. The patients were categorized according to their biopsy results as benign or malignant (subclassified by Gleason group grade), and the two groups were compared. Results: The average PI-RADS 3 ratio was 0.032 ± 0.002. There were 230 (74.7%) patients in the benign group and 78 (25.3%) patients in the malignant group. There was a statistically significant difference detected in average prostate volumes (p < 0.001), dPSA values (p = 0.001), and PI-RADS 3 ratios (p < 0.001). The receiver operating curve analysis of PI-RADS 3 ratio indicated an area under the curve of 0.643 ± 0.037. The optimal cut-off point was 0.026 with a sensitivity of 58.97% and a specificity of 66.96%. A positive, albeit weak, statistically significant relationship was found between PIRADS-3 ratios and dPSA values (rs ρ = 0.261 and p < 0.001). Conclusion: PI-RADS 3 ratio may serve as an auxiliary clinical parameter alongside age, dPSA, and lesion volume alone in identifying more refined candidates for biopsy in the goal of patient care individualization.
- 12 December 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (6) , 1459-1465
Open AccessPredictive impact of PI-RADS 3 lesion volume/total prostate volume ratio in prostate cancer diagnosis in biopsy-naïve patients
Background/aim: To assess the potential of the ratio between PI-RADS 3 lesion volume and total prostate volume as a predictive parameter for guiding the decision to perform a biopsy in patients presenting with PI-RADS 3 lesions on multiparametric prostate magnetic resonance imaging (mpMRI). Materials and methods: A total of 749 patients who underwent mpMRI due to suspected prostate cancer between January 2014 and August 2023 were scanned. Based on predefined inclusion and exclusion criteria, 308 patients were included. Age, total prostate-specific antigen (PSA) value, prostate volume measured in mpMRI, mpMRI result, PI-RADS 3 lesion volume, and biopsy results were collected. The PI-RADS 3 ratio was calculated as PI-RADS 3 lesion volume/total prostate volume. PSA density (dPSA) was calculated. The patients were categorized according to their biopsy results as benign or malignant (subclassified by Gleason group grade), and the two groups were compared. Results: The average PI-RADS 3 ratio was 0.032 ± 0.002. There were 230 (74.7%) patients in the benign group and 78 (25.3%) patients in the malignant group. There was a statistically significant difference detected in average prostate volumes (p < 0.001), dPSA values (p = 0.001), and PI-RADS 3 ratios (p < 0.001). The receiver operating curve analysis of PI-RADS 3 ratio indicated an area under the curve of 0.643 ± 0.037. The optimal cut-off point was 0.026 with a sensitivity of 58.97% and a specificity of 66.96%. A positive, albeit weak, statistically significant relationship was found between PIRADS-3 ratios and dPSA values (rs ρ = 0.261 and p < 0.001). Conclusion: PI-RADS 3 ratio may serve as an auxiliary clinical parameter alongside age, dPSA, and lesion volume alone in identifying more refined candidates for biopsy in the goal of patient care individualization.
- Open Access
- 20 October 2025
- Published by Pera Yayıncılık Hizmetleri in The New Journal of Urology
- p. 139
Efficacy of the HALP Score in Predicting Progression in Patients Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer
Objective: This study investigated the prognostic value of the HALP score, comprising haemoglobin, albumin, lymphocyte, and platelet parameters, on progression and progression-free survival (PFS) in patients undergoing radical cystectomy (RC) for non-metastatic muscle-invasive bladder cancer (MIBC). Material and Methods: A retrospective analysis was conducted on 134 MIBC patients who underwent RC between February 2014 and January 2024. The HALP score was calculated using the formula: HALP = (haemoglobin × albumin × lymphocytes) / platelets. Associations between HALP score, clinicopathological parameters, progression, and PFS were assessed via Kaplan-Meier survival analysis, ROC curve analysis, and multivariate logistic regression. Results: The median HALP score was significantly lower in patients with disease progression (29.19 [IQR: 19.17–41.81]) compared to those without progression (37.55 [IQR: 29.61–52.25]; p = 0.021). Patients with a HALP score <36.38 had a mean PFS of 68.8 months (95% CI: 52.6–85.1), compared to 82.4 months (95% CI: 66.5–98.2) in patients with a HALP score ≥36.38 (p=0.021). ROC analysis yielded an AUC of 0.619 (95% CI: 0.518–0.721) for predicting progression, with sensitivity and specificity of 54.9% and 55.4%, respectively. Perineural invasion (PNI) emerged as an independent prognostic factor for progression (OR=2.56, 95% CI: 1.011–6.482, p=0.047), and low preoperative albumin levels significantly increased progression risk (p=0.032). Conclusions: Although the HALP score is a statistically significant prognostic marker for predicting progression in patients with MIBC, it has limited predictive power. Our results demonstrate the potential of the HALP score as a helpful tool in individualised treatment approaches. However, the prognostic value of the HALP score needs to be confirmed in prospective and multicentre studies in larger patient populations.
- 20 October 2025
- Published by Pera Yayıncılık Hizmetleri in The New Journal of Urology
- p. 139
Open AccessEfficacy of the HALP Score in Predicting Progression in Patients Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer
Objective: This study investigated the prognostic value of the HALP score, comprising haemoglobin, albumin, lymphocyte, and platelet parameters, on progression and progression-free survival (PFS) in patients undergoing radical cystectomy (RC) for non-metastatic muscle-invasive bladder cancer (MIBC). Material and Methods: A retrospective analysis was conducted on 134 MIBC patients who underwent RC between February 2014 and January 2024. The HALP score was calculated using the formula: HALP = (haemoglobin × albumin × lymphocytes) / platelets. Associations between HALP score, clinicopathological parameters, progression, and PFS were assessed via Kaplan-Meier survival analysis, ROC curve analysis, and multivariate logistic regression. Results: The median HALP score was significantly lower in patients with disease progression (29.19 [IQR: 19.17–41.81]) compared to those without progression (37.55 [IQR: 29.61–52.25]; p = 0.021). Patients with a HALP score <36.38 had a mean PFS of 68.8 months (95% CI: 52.6–85.1), compared to 82.4 months (95% CI: 66.5–98.2) in patients with a HALP score ≥36.38 (p=0.021). ROC analysis yielded an AUC of 0.619 (95% CI: 0.518–0.721) for predicting progression, with sensitivity and specificity of 54.9% and 55.4%, respectively. Perineural invasion (PNI) emerged as an independent prognostic factor for progression (OR=2.56, 95% CI: 1.011–6.482, p=0.047), and low preoperative albumin levels significantly increased progression risk (p=0.032). Conclusions: Although the HALP score is a statistically significant prognostic marker for predicting progression in patients with MIBC, it has limited predictive power. Our results demonstrate the potential of the HALP score as a helpful tool in individualised treatment approaches. However, the prognostic value of the HALP score needs to be confirmed in prospective and multicentre studies in larger patient populations.
- Open Access
- 29 June 2025
- Published by Pera Yayıncılık Hizmetleri in The New Journal of Urology
- Vol. 20 (2) , 104
Novel Hematologic Markers for Risk Stratification in Bladder Cancer Patients Receiving BCG Treatment
Novel Hematologic Markers for Risk Stratification in Bladder Cancer Patients Receiving BCG Treatment
- 29 June 2025
- Published by Pera Yayıncılık Hizmetleri in The New Journal of Urology
- Vol. 20 (2) , 104
Open AccessNovel Hematologic Markers for Risk Stratification in Bladder Cancer Patients Receiving BCG Treatment
Novel Hematologic Markers for Risk Stratification in Bladder Cancer Patients Receiving BCG Treatment
- Open Access
- 1 January 2025
- Published by Archivos Espanoles de Urologia in Archivos Espanoles de Urologia
- Vol. 78 (9) , 1171-1177
Relationship between Serum Adropin Levels and Erectile Dysfunction
Aim: This study aimed to assess the relationship between serum adropin...
- 1 January 2025
- Published by Archivos Espanoles de Urologia in Archivos Espanoles de Urologia
- Vol. 78 (9) , 1171-1177
Open AccessRelationship between Serum Adropin Levels and Erectile Dysfunction
Aim: This study aimed to assess the relationship between serum adropin...
- 26 June 2024
- Published by Wiley in The Prostate
- Vol. 84 (13) , 1244-1250
The predictive impact of hematological inflammatory markers in detecting prostate cancer in patients with PI‐RADS 3 lesions on multiparametric magnetic resonance imaging
Background: The diagnostic accuracy of suspicious lesions that are classified as PI‐RADS 3 in multiparametric prostate magnetic‐resonance imaging (mpMRI) is controversial. This study aims to assess the predictive capacity of hematological inflammatory markers such as neutrophil‐lymphocyte ratio (NLR), pan‐immune‐inflammation value (PIV), and systemic immune‐response index (SIRI) in detecting prostate cancer in PI‐RADS 3 lesions.Methods: 276 patients who underwent mpMRI and subsequent prostate biopsy after PI‐RADS 3 lesion detection were included in the study. According to the biopsy results, the patients were distributed to two groups as prostate cancer (PCa) and no cancer (non‐PCa). Data concerning age, PSA, prostate volume, PSA density, PI‐RADS 3 lesion size, prostate biopsy results, monocyte counts (109/L), lymphocyte counts (109/L), platelet counts (109/L), neutrophils count (109/L) were recorded from the complete blood count. From these data; PIV value is obtained by monocyte × neutrophil × platelet/lymphocyte, NLR by neutrophil/lymphocyte, and SIRI by monocyte number × NLR.Results: Significant variations in neutrophil, lymphocyte, and monocyte levels between PCa and non‐PCa patient groups were detected (p = 0.009, p = 0.001, p = 0.005 respectively, p < 0.05). NLR, PIV, and SIRI exhibited significant differences, with higher values in PCa patients (p = 0.004, p = 0.001, p < 0.001 respectively, p < 0.05). The area under curve of SIRI was 0.729, with a cut‐off value of 1.20 and with a sensitivity 57.70%, and a specificity of 68.70%.Conclusion: SIRI outperformed NLR and PIV in detecting PCa in PI‐RADS 3 lesions, showcasing its potential as a valuable biomarker. Implementation of this parameter to possible future nomograms has the potential to individualize and risk‐stratify the patients in prostate biopsy decision.
- 26 June 2024
- Published by Wiley in The Prostate
- Vol. 84 (13) , 1244-1250
The predictive impact of hematological inflammatory markers in detecting prostate cancer in patients with PI‐RADS 3 lesions on multiparametric magnetic resonance imaging
Background: The diagnostic accuracy of suspicious lesions that are classified as PI‐RADS 3 in multiparametric prostate magnetic‐resonance imaging (mpMRI) is controversial. This study aims to assess the predictive capacity of hematological inflammatory markers such as neutrophil‐lymphocyte ratio (NLR), pan‐immune‐inflammation value (PIV), and systemic immune‐response index (SIRI) in detecting prostate cancer in PI‐RADS 3 lesions.Methods: 276 patients who underwent mpMRI and subsequent prostate biopsy after PI‐RADS 3 lesion detection were included in the study. According to the biopsy results, the patients were distributed to two groups as prostate cancer (PCa) and no cancer (non‐PCa). Data concerning age, PSA, prostate volume, PSA density, PI‐RADS 3 lesion size, prostate biopsy results, monocyte counts (109/L), lymphocyte counts (109/L), platelet counts (109/L), neutrophils count (109/L) were recorded from the complete blood count. From these data; PIV value is obtained by monocyte × neutrophil × platelet/lymphocyte, NLR by neutrophil/lymphocyte, and SIRI by monocyte number × NLR.Results: Significant variations in neutrophil, lymphocyte, and monocyte levels between PCa and non‐PCa patient groups were detected (p = 0.009, p = 0.001, p = 0.005 respectively, p < 0.05). NLR, PIV, and SIRI exhibited significant differences, with higher values in PCa patients (p = 0.004, p = 0.001, p < 0.001 respectively, p < 0.05). The area under curve of SIRI was 0.729, with a cut‐off value of 1.20 and with a sensitivity 57.70%, and a specificity of 68.70%.Conclusion: SIRI outperformed NLR and PIV in detecting PCa in PI‐RADS 3 lesions, showcasing its potential as a valuable biomarker. Implementation of this parameter to possible future nomograms has the potential to individualize and risk‐stratify the patients in prostate biopsy decision.
- Open Access
- 1 January 2024
- Published by XMLink in Investigative and Clinical Urology
- Vol. 65 (3) , 240-247
Inflammation indexes and machine-learning algorithm in predicting urethroplasty success
Tokuc E, et al. Investig Clin Urol. 2024 Mar;65:e26. https://doi.org/10.4111/icu.20230302
- 1 January 2024
- Published by XMLink in Investigative and Clinical Urology
- Vol. 65 (3) , 240-247
Open AccessInflammation indexes and machine-learning algorithm in predicting urethroplasty success
Tokuc E, et al. Investig Clin Urol. 2024 Mar;65:e26. https://doi.org/10.4111/icu.20230302
- 29 September 2023
- Published by Springer Nature in International Urology and Nephrology
- Vol. 56 (2) , 509-518
Pan-immune-inflammation value as a prognostic tool for overall survival and disease-free survival in non-metastatic muscle-invasive bladder cancer
Purpose To evaluate the association between preoperative pan-immune inflammation value (PIV) and overall survival (OS) and disease-free survival (DFS) in patients who underwent radical cystectomy for non-metastatic muscle-invasive bladder cancer. Methods A total of 119 patients with non-metastatic muscle-invasive bladder cancer who underwent radical cystectomy at our institution between January 2014 and January 2022 were included in this retrospective study. PIV was calculated using the formula (monocyte count × neutrophil count × platelet count)/lymphocyte count. Ideal cut-off values for PIV were determined using ROC curve analysis. Kaplan–Meier analysis was used to evaluate the impact of PIV on survival outcomes. Results The mean age of patients was 65 ± 14 years, and the mean follow-up duration was 36 months. The ideal cutoff value for PIV was determined to be 406.29, and a PIV above this value was associated with poorer OS (p < 0.001) (73 months vs. 21 months) and DFS (p = 0.002) (35 months vs 19 months). Higher neutrophil-to-lymphocyte ratio (NLR) values were also associated with poorer OS (p < 0.001) and DFS (p < 0.001), with similar effectiveness to PIV. PIV was found to be significantly more effective than platelet-to-lymphocyte ratio (PLR) and systemic immune inflammation index (SII) in predicting DFS. Conclusion Preoperative PIV may serve as an independent prognostic factor for OS in patients who undergo radical cystectomy with non-metastatic muscle-invasive bladder cancer. A high PIV value was associated with poorer survival outcomes. Prospective multicenter studies are needed to further validate the relationship between PIV and histopathological features of bladder cancer.
- 29 September 2023
- Published by Springer Nature in International Urology and Nephrology
- Vol. 56 (2) , 509-518
Pan-immune-inflammation value as a prognostic tool for overall survival and disease-free survival in non-metastatic muscle-invasive bladder cancer
Purpose To evaluate the association between preoperative pan-immune inflammation value (PIV) and overall survival (OS) and disease-free survival (DFS) in patients who underwent radical cystectomy for non-metastatic muscle-invasive bladder cancer. Methods A total of 119 patients with non-metastatic muscle-invasive bladder cancer who underwent radical cystectomy at our institution between January 2014 and January 2022 were included in this retrospective study. PIV was calculated using the formula (monocyte count × neutrophil count × platelet count)/lymphocyte count. Ideal cut-off values for PIV were determined using ROC curve analysis. Kaplan–Meier analysis was used to evaluate the impact of PIV on survival outcomes. Results The mean age of patients was 65 ± 14 years, and the mean follow-up duration was 36 months. The ideal cutoff value for PIV was determined to be 406.29, and a PIV above this value was associated with poorer OS (p < 0.001) (73 months vs. 21 months) and DFS (p = 0.002) (35 months vs 19 months). Higher neutrophil-to-lymphocyte ratio (NLR) values were also associated with poorer OS (p < 0.001) and DFS (p < 0.001), with similar effectiveness to PIV. PIV was found to be significantly more effective than platelet-to-lymphocyte ratio (PLR) and systemic immune inflammation index (SII) in predicting DFS. Conclusion Preoperative PIV may serve as an independent prognostic factor for OS in patients who undergo radical cystectomy with non-metastatic muscle-invasive bladder cancer. A high PIV value was associated with poorer survival outcomes. Prospective multicenter studies are needed to further validate the relationship between PIV and histopathological features of bladder cancer.